Large Clinical Study Demonstrates High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients; Results Presented at 2016 AACR Pancreatic Cancer Meeting

92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay

SAN DIEGO, May 13, 2016 -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical study results featuring the Company's Precision Cancer Monitoring® (PCM) platform were presented at the 2016 AACR Special Pancreatic Cancer Meeting in Orlando, Florida. The poster, entitled Detection and Quantification of ctDNA KRAS Mutations from Patients with Unresectable Pancreatic Cancer, was presented by Fernando Blanco, Ph.D., medical science liaison at Trovagene.

Highlights from the poster include:

 

Detection rate of circulating tumor DNA (ctDNA) KRAS in 210-patient study closely matches the published prevalence of KRAS mutations in pancreatic cancer (~90%)

ctDNA KRAS levels can be used to distinguish between locally advanced and metastatic cancer (p

Longitudinal monitoring of KRAS can be informative in determining responsiveness to therapy and to predict disease progression months in advance of imaging

The dataset is the largest prospective study exploring ctDNA KRAS in unresectable pancreatic cancer

 

"In this data set, we have shown the ability to detect KRAS mutations in pancreatic cancer patients with high sensitivity from a liquid biopsy," stated Julia Johansen, M.D., University of Copenhagen, Denmark and Lead Investigator. "The quantitative assessment of KRAS mutational load using ctDNA at baseline and over time has potential to become an important biomarker in the treatment of metastatic pancreatic cancer, given a high correlation to disease status and the reliability challenges with CA19-9, a biomarker often used in practice to monitor patients with metastatic cancer for progression."